Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 9, 2025PLoS PathogensOpen Access

Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYa WangSWShuo WuXLXingqiong Li

Discussion

Loading...

Member takes

Overview

Mice treated with STING agonists showed improved antiviral immune responses against chronic hepatitis B, suggesting new therapeutic options.

Key Points

  • This research aims to explore the antiviral and immune modulatory activities of STING agonists in a mouse model of hepatitis B infection.
  • Utilized STING knockout and human STING knock-in mouse models
  • Administered STING agonist diABZI at optimized doses
  • Conducted virological and RNA-seq analyses to assess immune response and HBV replication
  • STING agonist treatment activated robust innate and adaptive immune responses
  • Significantly suppressed HBV DNA replication in the liver
  • Detection of HBsAb in 25% of treated mice after 5 weeks

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69401efa2d562116f28f9929https://doi.org/10.1371/journal.ppat.1013709
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells2024 · 12 citations
  2. 2Present and future therapies of hepatitis B: From discovery to cure2015 · 319 citations
  3. 3Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection2022 · 21 citations
  4. 4Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B2022 · 7 citations
  5. 5Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B2015 · 203 citations